FDA Approves Bizengri (Zenocutuzumab) for NRG1 Fusion-Positive Cholangiocarcinoma, Developed by Merus and Partner Therapeutics
Subheading 1: First Targeted Therapy for NRG1 Fusion-Positive Cholangiocarcinoma
The FDA has granted accelerated approval for Bizengri (zenocutuzumab-zbco), developed by Merus N.V. and co-developed with Partner Therapeutics, Inc., for the treatment of unresectable, locally advanced or metastatic cholangiocarcinoma with NRG1 (neuregulin 1) fusions. Bizengri is an innovative bispecific antibody that simultaneously binds to HER2 and HER3 receptors on cancer cells, blocking the binding of NRG1 fusion proteins. This approval marks a significant milestone, offering a precision medicine approach for patients with NRG1 fusion mutations who previously had limited treatment options after standard chemotherapy.
Subheading 2: Demonstrated Efficacy and Safety in the eNRGy Phase 2 Trial
The accelerated approval is based on data from the eNRGy Phase 2 trial, which included 19 patients with NRG1 fusion-positive cholangiocarcinoma. The results showed an overall response rate (ORR) of 36.8% with Bizengri, with a duration of response (DOR) ranging from 2.8 to 12.9 months. The median progression-free survival (mPFS) was 9.2 months, demonstrating a significant improvement over existing second-line therapies.
Subheading 3: Strategic Collaboration Between Partner Therapeutics and Merus, and Financial Implications
Merus, the originator of Bizengri, entered into a licensing agreement with Partner Therapeutics in December 2024, granting Partner Therapeutics exclusive commercial rights in the United States. Under the agreement, Merus received an upfront payment and is eligible for milestone payments of up to $130 million, as well as royalties ranging from the high teens to the low twenties on net sales in the U.S. Partner Therapeutics plans to leverage this approval to accelerate the commercialization of Bizengri and expand its NRG1-targeted pipeline in the U.S., including potential applications in pancreatic cancer and non-small cell lung cancer (NSCLC).
Subheading 4: Expanding the Market for Rare and Difficult-to-Treat Cancers, and Increasing Competition in Targeted Therapies
The global cholangiocarcinoma market is projected to grow rapidly from approximately $583 million in 2025 to $2.42 billion by 2035. While Bizengri targets a rare mutation present in less than 1% of all cholangiocarcinoma patients, it is the first and only targeted therapy specifically designed for NRG1 fusions, giving it a unique market position. Industry analysts believe that the success of Bizengri will set a new standard of care and create a significant advantage over competing therapies in terms of survival benefits.
Subheading 5: The Need for Companion Diagnostics to Enable Personalized Precision Medicine
To ensure the successful adoption of Bizengri, it is essential to develop and implement companion diagnostics (CDx) and next-generation sequencing (NGS) assays to identify patients with NRG1 fusion-positive cholangiocarcinoma. Given the rarity of this mutation, early detection is crucial for identifying eligible patients and maximizing the impact of Bizengri. Post-approval, the availability of these diagnostics and the extent of reimbursement coverage by U.S. insurance providers will be key factors in determining the initial market penetration of Bizengri.
The FDA's accelerated approval of Bizengri, based on Phase 2 data, is noteworthy as it represents the first bispecific antibody targeting NRG1 fusions to be approved as a second-line treatment for cholangiocarcinoma. From an investor perspective, Partner Therapeutics' exclusive commercial rights, secured through a deal worth up to $130 million, position the company to capture a significant share of the cholangiocarcinoma market, which is projected to reach $2.42 billion by 2035. For clinical researchers, the efficacy data from the eNRGy trial, including an ORR of 36.8% and an mPFS of 9.2 months, are encouraging compared to existing pan-ErbB inhibitors, such as afatinib, which are often used off-label. In the long term, the approval of Bizengri is expected to drive the development and adoption of companion diagnostics, thereby lowering the barriers to entry for precision medicine in the rare cancer space.